Persistent symptoms and risk factors predicting prolonged time to symptom-free after SARS‑CoV‑2 infection: an analysis of the baseline examination of the German COVIDOM/NAPKON-POP cohort
Standard
Persistent symptoms and risk factors predicting prolonged time to symptom-free after SARS‑CoV‑2 infection: an analysis of the baseline examination of the German COVIDOM/NAPKON-POP cohort. / Shi, Yanyan; Strobl, Ralf; Apfelbacher, Christian; Bahmer, Thomas; Geisler, Ramsia; Heuschmann, Peter; Horn, Anna; Hoven, Hanno; Keil, Thomas; Krawczak, Michael; Krist, Lilian; Lemhöfer, Christina; Lieb, Wolfgang; Lorenz-Depiereux, Bettina; Mikolajczyk, Rafael; Montellano, Felipe A; Reese, Jens Peter; Schreiber, Stefan; Skoetz, Nicole; Störk, Stefan; Vehreschild, Jörg Janne; Witzenrath, Martin; Grill, Eva; NAPKON Study Group.
in: INFECTION, Jahrgang 51, Nr. 6, 12.2023, S. 1679-1694.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Persistent symptoms and risk factors predicting prolonged time to symptom-free after SARS‑CoV‑2 infection: an analysis of the baseline examination of the German COVIDOM/NAPKON-POP cohort
AU - Shi, Yanyan
AU - Strobl, Ralf
AU - Apfelbacher, Christian
AU - Bahmer, Thomas
AU - Geisler, Ramsia
AU - Heuschmann, Peter
AU - Horn, Anna
AU - Hoven, Hanno
AU - Keil, Thomas
AU - Krawczak, Michael
AU - Krist, Lilian
AU - Lemhöfer, Christina
AU - Lieb, Wolfgang
AU - Lorenz-Depiereux, Bettina
AU - Mikolajczyk, Rafael
AU - Montellano, Felipe A
AU - Reese, Jens Peter
AU - Schreiber, Stefan
AU - Skoetz, Nicole
AU - Störk, Stefan
AU - Vehreschild, Jörg Janne
AU - Witzenrath, Martin
AU - Grill, Eva
AU - NAPKON Study Group
AU - Addo, Marylyn Martina
N1 - © 2023. The Author(s).
PY - 2023/12
Y1 - 2023/12
N2 - PURPOSE: We aimed to assess symptoms in patients after SARS-CoV-2 infection and to identify factors predicting prolonged time to symptom-free.METHODS: COVIDOM/NAPKON-POP is a population-based prospective cohort of adults whose first on-site visits were scheduled ≥ 6 months after a positive SARS-CoV-2 PCR test. Retrospective data including self-reported symptoms and time to symptom-free were collected during the survey before a site visit. In the survival analyses, being symptom-free served as the event and time to be symptom-free as the time variable. Data were visualized with Kaplan-Meier curves, differences were tested with log-rank tests. A stratified Cox proportional hazard model was used to estimate adjusted hazard ratios (aHRs) of predictors, with aHR < 1 indicating a longer time to symptom-free.RESULTS: Of 1175 symptomatic participants included in the present analysis, 636 (54.1%) reported persistent symptoms after 280 days (SD 68) post infection. 25% of participants were free from symptoms after 18 days [quartiles: 14, 21]. Factors associated with prolonged time to symptom-free were age 49-59 years compared to < 49 years (aHR 0.70, 95% CI 0.56-0.87), female sex (aHR 0.78, 95% CI 0.65-0.93), lower educational level (aHR 0.77, 95% CI 0.64-0.93), living with a partner (aHR 0.81, 95% CI 0.66-0.99), low resilience (aHR 0.65, 95% CI 0.47-0.90), steroid treatment (aHR 0.22, 95% CI 0.05-0.90) and no medication (aHR 0.74, 95% CI 0.62-0.89) during acute infection.CONCLUSION: In the studied population, COVID-19 symptoms had resolved in one-quarter of participants within 18 days, and in 34.5% within 28 days. Over half of the participants reported COVID-19-related symptoms 9 months after infection. Symptom persistence was predominantly determined by participant's characteristics that are difficult to modify.
AB - PURPOSE: We aimed to assess symptoms in patients after SARS-CoV-2 infection and to identify factors predicting prolonged time to symptom-free.METHODS: COVIDOM/NAPKON-POP is a population-based prospective cohort of adults whose first on-site visits were scheduled ≥ 6 months after a positive SARS-CoV-2 PCR test. Retrospective data including self-reported symptoms and time to symptom-free were collected during the survey before a site visit. In the survival analyses, being symptom-free served as the event and time to be symptom-free as the time variable. Data were visualized with Kaplan-Meier curves, differences were tested with log-rank tests. A stratified Cox proportional hazard model was used to estimate adjusted hazard ratios (aHRs) of predictors, with aHR < 1 indicating a longer time to symptom-free.RESULTS: Of 1175 symptomatic participants included in the present analysis, 636 (54.1%) reported persistent symptoms after 280 days (SD 68) post infection. 25% of participants were free from symptoms after 18 days [quartiles: 14, 21]. Factors associated with prolonged time to symptom-free were age 49-59 years compared to < 49 years (aHR 0.70, 95% CI 0.56-0.87), female sex (aHR 0.78, 95% CI 0.65-0.93), lower educational level (aHR 0.77, 95% CI 0.64-0.93), living with a partner (aHR 0.81, 95% CI 0.66-0.99), low resilience (aHR 0.65, 95% CI 0.47-0.90), steroid treatment (aHR 0.22, 95% CI 0.05-0.90) and no medication (aHR 0.74, 95% CI 0.62-0.89) during acute infection.CONCLUSION: In the studied population, COVID-19 symptoms had resolved in one-quarter of participants within 18 days, and in 34.5% within 28 days. Over half of the participants reported COVID-19-related symptoms 9 months after infection. Symptom persistence was predominantly determined by participant's characteristics that are difficult to modify.
U2 - 10.1007/s15010-023-02043-6
DO - 10.1007/s15010-023-02043-6
M3 - SCORING: Journal article
C2 - 37231313
VL - 51
SP - 1679
EP - 1694
JO - INFECTION
JF - INFECTION
SN - 0300-8126
IS - 6
ER -